This site has not been optimised for Internet Explorer due to Microsoft no longer providing support for the browser. Please view this site using another browser such as Google Chrome or Microsoft Edge.
Te Pū rauemi KOWHEORI-19 COVID-19 resource hub

Support for people working in health during the COVID-19 pandemic. Find information about how you can support yourselves and others, including consumers, teams and colleagues which complements and aligns with Ministry of Health resources.

Kia āta kōwhiri Choosing Wisely

The Choosing Wisely campaign seeks to reduce harm from unnecessary and low-value tests and treatment.

Back to previous page

ALERT 5: Low molecular weight heparin (LMWH) in renal impairment

9 Dec 2021

This Alert was prompted by a review in 2004 by the New Zealand Pharmacovigilance Centre of 33 cases reports of enoxaparin related bleeding or haemorrhage and 3 case reports of major bleeding with dalteparin. There were five reports of death and four reports of life threatening haemorrhage with enoxaparin. Of these patients, six out of nine had renal impairment and seven out of nine patients were aged over 70 years. Haematological opinion at that time indicated that elderly patients are not more at risk of bleeding complications with the LMWHs providing the dose is adjusted for weight and renal function.